Free Trial
→ Market Panic: Trump Just Dropped a Bomb on Your Stocks (From American Alternative) (Ad) Free KURA Stock Alerts

Kura Oncology (KURA) Financials

Kura Oncology logo
$5.54 -0.42 (-7.05%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$5.54 0.00 (0.00%)
As of 08/8/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Kura Oncology

Annual Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -136 -153 -174
Consolidated Net Income / (Loss)		 -136 -153 -174
Net Income / (Loss) Continuing Operations		 -136 -153 -174
Total Pre-Tax Income 		-136 -153 -172
Total Operating Income		 -140 -166 -193
Total Gross Profit		 0.00 0.00 54
Total Revenue		 0.00 0.00 54
Operating Revenue		 0.00 0.00 54
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 140 166 247
Selling, General & Admin Expense		 47 51 77
Research & Development Expense		 93 115 170
Total Other Income / (Expense), net		 4.03 13 21
Interest Expense		 0.23 1.55 1.62
Interest & Investment Income		 4.25 15 23
Income Tax Expense		 0.00 0.00 2.02
Basic Earnings per Share		 ($2.03) ($2.08) ($2.02)
Weighted Average Basic Shares Outstanding		 66.99M 73.23M 86.16M
Diluted Earnings per Share		 ($2.03) ($2.08) ($2.02)
Weighted Average Diluted Shares Outstanding		 66.99M 73.23M 86.16M
Weighted Average Basic & Diluted Shares Outstanding		 68.44M 76.14M 80.75M

Quarterly Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -33 -34 -37 -37 -44 -50 -50 -53 -21
Consolidated Net Income / (Loss)		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Net Income / (Loss) Continuing Operations		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Total Pre-Tax Income 		-36 -33 -34 -37 -39 -43 -50 -51 -54 -17
Total Operating Income		 -37 -35 -37 -40 -42 -47 -54 -56 -60 -22
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 54
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 54
Total Operating Expenses		 37 35 37 40 42 47 54 56 60 76
Selling, General & Admin Expense		 12 12 11 12 13 14 18 17 18 24
Research & Development Expense		 25 23 25 28 29 33 36 40 42 52
Total Other Income / (Expense), net		 1.09 2.04 2.50 2.83 3.87 3.98 4.93 5.57 5.48 5.26
Interest Expense		 0.00 0.23 0.36 0.39 0.40 0.39 0.40 0.41 0.41 0.40
Interest & Investment Income		 1.09 2.27 2.86 3.22 4.28 4.37 5.33 5.97 5.89 5.66
Basic Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Weighted Average Basic Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Diluted Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Weighted Average Diluted Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Weighted Average Basic & Diluted Shares Outstanding		 66.90M 68.44M 68.44M 74.24M 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M

Annual Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -39 -14 187
Net Cash From Operating Activities		 -110 -125 134
Net Cash From Continuing Operating Activities		 -110 -125 134
Net Income / (Loss) Continuing Operations		 -136 -153 -174
Consolidated Net Income / (Loss)		 -136 -153 -174
Depreciation Expense		 0.76 0.85 0.85
Amortization Expense		 1.68 -8.94 -13
Non-Cash Adjustments To Reconcile Net Income		 27 27 35
Changes in Operating Assets and Liabilities, net		 -3.55 8.50 285
Net Cash From Investing Activities		 33 16 -102
Net Cash From Continuing Investing Activities		 33 16 -102
Purchase of Property, Plant & Equipment		 -0.63 -0.17 -0.47
Purchase of Investments		 -271 -410 -659
Sale and/or Maturity of Investments		 304 426 558
Net Cash From Financing Activities		 39 95 154
Net Cash From Continuing Financing Activities		 39 95 154
Repayment of Debt		 -0.58 0.00 0.00
Issuance of Debt		 10 0.00 0.00
Issuance of Common Equity		 29 95 154
Cash Interest Paid		 0.07 1.06 1.10

Quarterly Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 52 -39 -25 22 -20 8.58 4.19 3.68 4.30 175
Net Cash From Operating Activities		 -21 -27 -36 -26 -29 -34 -49 -43 -43 269
Net Cash From Continuing Operating Activities		 -21 -27 -36 -26 -29 -34 -49 -43 -43 269
Net Income / (Loss) Continuing Operations		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Consolidated Net Income / (Loss)		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Depreciation Expense		 0.19 0.21 0.21 0.21 0.22 0.21 0.23 0.20 0.21 0.20
Amortization Expense		 0.37 -0.58 -1.57 -1.99 -2.77 -2.61 -3.15 -3.42 -3.30 -2.75
Non-Cash Adjustments To Reconcile Net Income		 6.59 7.15 7.02 7.30 7.37 5.70 8.74 8.97 7.82 9.32
Changes in Operating Assets and Liabilities, net		 7.35 -0.19 -7.46 6.03 4.76 5.17 -5.15 2.56 6.24 282
Net Cash From Investing Activities		 72 -47 11 -46 8.56 42 -95 43 46 -95
Net Cash From Continuing Investing Activities		 72 -47 11 -46 8.56 42 -95 43 46 -95
Purchase of Property, Plant & Equipment		 -0.38 -0.01 -0.04 -0.10 -0.02 -0.02 -0.08 -0.02 - -0.37
Purchase of Investments		 -57 -106 -74 -140 -97 -100 -195 -162 -62 -241
Sale and/or Maturity of Investments		 129 59 85 93 105 142 100 205 107 146
Net Cash From Financing Activities		 0.88 35 0.00 94 0.08 0.69 148 3.04 2.20 0.81
Net Cash From Continuing Financing Activities		 0.88 35 0.00 94 0.08 0.69 148 3.04 2.20 0.81
Issuance of Common Equity		 0.88 25 0.00 94 0.08 0.69 148 3.04 2.20 0.81

Annual Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 456 449 760
Total Current Assets		 446 432 745
Cash & Equivalents		 52 37 224
Short-Term Investments		 386 387 503
Prepaid Expenses		 8.44 8.52 17
Plant, Property, & Equipment, net		 2.54 1.86 1.68
Total Noncurrent Assets		 7.34 15 14
Other Noncurrent Operating Assets		 7.34 15 14
Total Liabilities & Shareholders' Equity		 456 449 760
Total Liabilities		 36 52 347
Total Current Liabilities		 24 35 79
Short-Term Debt		 - 0.00 2.61
Accounts Payable		 22 34 50
Current Deferred Revenue		 - 0.00 24
Other Current Liabilities		 2.32 1.51 1.88
Total Noncurrent Liabilities		 12 16 268
Long-Term Debt		 9.16 9.33 6.92
Noncurrent Deferred Revenue		 - 0.00 254
Other Noncurrent Operating Liabilities		 2.81 7.07 6.99
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 420 397 414
Total Preferred & Common Equity		 420 397 414
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 420 397 414
Common Stock		 997 1,120 1,308
Retained Earnings		 -569 -721 -895
Accumulated Other Comprehensive Income / (Loss)		 -8.03 -1.27 0.76

Quarterly Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 448 426 495 474 554 515 479
Total Current Assets		 436 416 486 460 538 500 463
Cash & Equivalents		 91 27 49 29 42 45 49
Short-Term Investments		 337 379 428 424 486 446 406
Prepaid Expenses		 8.62 11 8.67 7.32 11 8.25 7.89
Plant, Property, & Equipment, net		 2.73 2.37 2.25 2.06 1.71 1.52 1.32
Total Noncurrent Assets		 8.86 7.16 6.84 12 14 14 14
Other Noncurrent Operating Assets		 8.86 7.16 6.84 12 14 14 14
Total Liabilities & Shareholders' Equity		 448 426 495 474 554 515 479
Total Liabilities		 28 31 35 44 49 49 55
Total Current Liabilities		 25 19 24 28 32 33 40
Short-Term Debt		 - - - - - 0.85 1.72
Accounts Payable		 22 17 22 26 31 31 37
Other Current Liabilities		 2.30 2.33 2.35 1.68 1.36 1.47 1.69
Total Noncurrent Liabilities		 3.62 12 11 16 17 16 15
Long-Term Debt		 - 9.20 9.24 9.29 9.38 8.58 7.76
Other Noncurrent Operating Liabilities		 3.62 2.36 1.92 7.02 7.18 7.02 6.94
Total Equity & Noncontrolling Interests		 420 395 460 430 505 466 424
Total Preferred & Common Equity		 420 395 460 430 505 466 424
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 420 395 460 430 505 466 424
Common Stock		 965 1,004 1,105 1,112 1,277 1,288 1,299
Retained Earnings		 -536 -603 -640 -679 -771 -822 -876
Accumulated Other Comprehensive Income / (Loss)		 -9.42 -5.90 -5.22 -3.54 -0.82 -0.46 1.12

Annual Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -9.14% -26.54% -17.87%
EBIT Growth		 -6.56% -18.55% -16.52%
NOPAT Growth		 -6.56% -18.55% -16.52%
Net Income Growth		 -4.12% -12.36% -13.99%
EPS Growth		 -3.05% -2.46% 2.88%
Operating Cash Flow Growth		 -5.27% -13.41% 207.61%
Free Cash Flow Firm Growth		 -5.24% -6.51% 241.38%
Invested Capital Growth		 24.69% -102.97% -1,653.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -3.21% -8.51% 10.55%
EBIT Q/Q Growth		 -1.54% -7.53% 11.18%
NOPAT Q/Q Growth		 -1.54% -7.53% 11.18%
Net Income Q/Q Growth		 -0.27% -6.77% 11.93%
EPS Q/Q Growth		 0.49% -2.97% 14.41%
Operating Cash Flow Q/Q Growth		 -2.96% -6.65% 179.42%
Free Cash Flow Firm Q/Q Growth		 -2.81% -4.41% 205.63%
Invested Capital Q/Q Growth		 -4.84% -29.81% -1,279.49%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% -380.39%
Operating Margin		 0.00% 0.00% -358.55%
EBIT Margin		 0.00% 0.00% -358.55%
Profit (Net Income) Margin		 0.00% 0.00% -322.89%
Tax Burden Percent		 100.00% 100.00% 101.17%
Interest Burden Percent		 97.12% 92.06% 89.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.31% -37.34% -42.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -31.96%
Return on Assets (ROA)		 0.00% 0.00% -28.78%
Return on Common Equity (ROCE)		 -29.31% -37.34% -42.91%
Return on Equity Simple (ROE_SIMPLE)		 -32.32% -38.42% -42.06%
Net Operating Profit after Tax (NOPAT)		 -98 -116 -135
NOPAT Margin		 0.00% 0.00% -250.98%
Net Nonoperating Expense Percent (NNEP)		 -8.01% -8.67% -6.84%
Return On Investment Capital (ROIC_SIMPLE)		 -22.80% -28.54% -31.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 143.11%
R&D to Revenue		 0.00% 0.00% 315.44%
Operating Expenses to Revenue		 0.00% 0.00% 458.55%
Earnings before Interest and Taxes (EBIT)		 -140 -166 -193
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -137 -174 -205
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.98 2.69 1.64
Price to Tangible Book Value (P/TBV)		 1.98 2.69 1.64
Price to Revenue (P/Rev)		 0.00 0.00 12.57
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.02 0.02 0.02
Long-Term Debt to Equity		 0.02 0.02 0.02
Financial Leverage		 -1.02 -1.03 -1.40
Leverage Ratio		 1.07 1.11 1.49
Compound Leverage Factor		 1.04 1.02 1.33
Debt to Total Capital		 2.13% 2.30% 2.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.62%
Long-Term Debt to Total Capital		 2.13% 2.30% 1.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.87% 97.70% 97.75%
Debt to EBITDA		 -0.07 -0.05 -0.05
Net Debt to EBITDA		 3.12 2.38 3.50
Long-Term Debt to EBITDA		 -0.07 -0.05 -0.03
Debt to NOPAT		 -0.09 -0.08 -0.07
Net Debt to NOPAT		 4.38 3.57 5.31
Long-Term Debt to NOPAT		 -0.09 -0.08 -0.05
Altman Z-Score		 12.18 10.00 -0.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 18.56 12.26 9.46
Quick Ratio		 18.21 12.02 9.24
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -101 -107 152
Operating Cash Flow to CapEx		 -17,581.79% -74,300.00% 28,456.99%
Free Cash Flow to Firm to Interest Expense		 -439.77 -69.24 93.66
Operating Cash Flow to Interest Expense		 -480.62 -80.58 82.96
Operating Cash Flow Less CapEx to Interest Expense		 -483.35 -80.69 82.67
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 30.43
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -8.55 -17 -304
Invested Capital Turnover		 0.00 0.00 -0.34
Increase / (Decrease) in Invested Capital		 2.80 -8.80 -287
Enterprise Value (EV)		 401 653 -41
Market Capitalization		 830 1,068 677
Book Value per Share		 $6.28 $5.35 $5.32
Tangible Book Value per Share		 $6.28 $5.35 $5.32
Total Capital		 429 407 423
Total Debt		 9.16 9.33 9.52
Total Long-Term Debt		 9.16 9.33 6.92
Net Debt		 -429 -415 -718
Capital Expenditures (CapEx)		 0.63 0.17 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -27 -59
Debt-free Net Working Capital (DFNWC)		 422 397 669
Net Working Capital (NWC)		 422 397 666
Net Nonoperating Expense (NNE)		 38 37 39
Net Nonoperating Obligations (NNO)		 -429 -415 -718
Total Depreciation and Amortization (D&A)		 2.44 -8.09 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -108.89%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,241.07%
Net Working Capital to Revenue		 0.00% 0.00% 1,236.23%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.03) ($2.08) ($2.02)
Adjusted Weighted Average Basic Shares Outstanding		 66.99M 73.23M 86.16M
Adjusted Diluted Earnings per Share		 ($2.03) ($2.08) ($2.02)
Adjusted Weighted Average Diluted Shares Outstanding		 66.99M 73.23M 86.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 68.44M 76.14M 80.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -98 -116 -135
Normalized NOPAT Margin		 0.00% 0.00% -250.98%
Pre Tax Income Margin		 0.00% 0.00% -319.15%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -610.76 -107.04 -119.33
NOPAT to Interest Expense		 -427.53 -74.93 -83.53
EBIT Less CapEx to Interest Expense		 -613.50 -107.15 -119.62
NOPAT Less CapEx to Interest Expense		 -430.27 -75.04 -83.82
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -11.45% -13.67% -20.40% -21.61% -24.96% -38.36% -51.23% -42.71% -39.88% 49.16%
EBIT Growth		 -8.66% -6.41% -11.54% -13.22% -16.07% -33.01% -48.91% -41.00% -40.99% 51.98%
NOPAT Growth		 -8.66% -6.41% -11.54% -13.22% -16.07% -33.01% -48.91% -41.00% -40.99% 51.98%
Net Income Growth		 -6.41% -1.13% -4.98% -6.92% -8.73% -29.21% -45.37% -36.75% -40.94% 55.09%
EPS Growth		 -6.00% 2.00% -2.04% -1.92% 5.66% -12.24% -18.00% -11.32% -26.00% 61.82%
Operating Cash Flow Growth		 14.57% -13.54% -11.47% 15.57% -38.16% -29.32% -36.16% -66.02% -49.65% 884.46%
Free Cash Flow Firm Growth		 -7.30% -1.75% 8.54% 37.06% 9.70% 12.70% 3.34% -52.15% -35.54% 1,233.13%
Invested Capital Growth		 15.84% 24.69% 60.34% -950.46% -63.93% -102.97% -734.67% -98.91% -64.99% -1,653.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4.88% 1.39% -6.76% -10.14% -7.77% -9.19% -16.69% -3.94% -5.63% 60.31%
EBIT Q/Q Growth		 -3.57% 3.93% -4.01% -9.40% -6.17% -10.10% -16.45% -3.58% -6.17% 62.50%
NOPAT Q/Q Growth		 -3.57% 3.93% -4.01% -9.40% -6.17% -10.10% -16.45% -3.58% -6.17% 62.50%
Net Income Q/Q Growth		 -2.11% 6.73% -2.88% -9.11% -3.84% -10.84% -15.75% -2.65% -7.02% 64.68%
EPS Q/Q Growth		 -1.92% 7.55% -2.04% -6.00% 5.66% -10.00% -7.27% 0.00% -6.78% 66.67%
Operating Cash Flow Q/Q Growth		 30.75% -26.27% -35.21% 28.59% -13.31% -18.19% -42.37% 12.93% -2.14% 719.55%
Free Cash Flow Firm Q/Q Growth		 17.50% -0.96% -1.80% 25.77% -18.38% 2.40% -12.71% -16.84% -5.45% 915.97%
Invested Capital Q/Q Growth		 -963.10% -4.84% 82.26% -431.11% -65.91% -29.81% 27.03% -26.57% -37.61% -1,279.49%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -46.39%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41.67%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41.67%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -35.66%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 111.73%
Interest Burden Percent		 97.02% 94.19% 93.17% 92.93% 90.89% 91.50% 90.95% 90.13% 90.85% 76.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.42% -29.31% -31.55% -30.77% -33.65% -37.34% -37.34% -39.27% -46.28% -42.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.71%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.18%
Return on Common Equity (ROCE)		 -28.42% -29.31% -31.55% -30.77% -33.65% -37.34% -37.34% -39.27% -46.28% -42.91%
Return on Equity Simple (ROE_SIMPLE)		 -32.28% 0.00% -34.78% -30.43% -33.25% 0.00% -33.28% -39.00% -46.62% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -25 -26 -28 -30 -33 -38 -39 -42 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29.17%
Net Nonoperating Expense Percent (NNEP)		 -2.04% -1.80% -1.93% -2.00% -2.04% -2.38% -2.50% -2.39% -2.81% -0.62%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.73% - - - -8.05% - - - -3.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 44.67%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 141.67%
Earnings before Interest and Taxes (EBIT)		 -37 -35 -37 -40 -42 -47 -54 -56 -60 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -36 -38 -42 -45 -49 -57 -60 -63 -25
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.18 1.98 2.12 1.58 1.57 2.69 3.14 3.37 3.53 1.64
Price to Tangible Book Value (P/TBV)		 2.18 1.98 2.12 1.58 1.57 2.69 3.14 3.37 3.53 1.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Long-Term Debt to Equity		 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Financial Leverage		 -1.02 -1.02 -1.01 -1.01 -1.03 -1.03 -1.02 -1.03 -1.04 -1.40
Leverage Ratio		 1.06 1.07 1.06 1.06 1.09 1.11 1.09 1.09 1.12 1.49
Compound Leverage Factor		 1.03 1.01 0.99 0.99 0.99 1.01 0.99 0.98 1.01 1.14
Debt to Total Capital		 0.00% 2.13% 2.28% 1.97% 2.11% 2.30% 1.82% 1.98% 2.19% 2.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.40% 0.62%
Long-Term Debt to Total Capital		 0.00% 2.13% 2.28% 1.97% 2.11% 2.30% 1.82% 1.80% 1.79% 1.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 97.87% 97.72% 98.03% 97.89% 97.70% 98.18% 98.02% 97.81% 97.75%
Debt to EBITDA		 0.00 -0.07 -0.06 -0.06 -0.06 -0.05 -0.05 -0.04 -0.04 -0.05
Net Debt to EBITDA		 0.00 3.12 2.76 3.09 2.77 2.38 2.68 2.28 1.95 3.50
Long-Term Debt to EBITDA		 0.00 -0.07 -0.06 -0.06 -0.06 -0.05 -0.05 -0.04 -0.03 -0.03
Debt to NOPAT		 0.00 -0.09 -0.09 -0.09 -0.09 -0.08 -0.07 -0.07 -0.06 -0.07
Net Debt to NOPAT		 0.00 4.38 3.95 4.51 4.11 3.57 4.03 3.44 2.93 5.31
Long-Term Debt to NOPAT		 0.00 -0.09 -0.09 -0.09 -0.09 -0.08 -0.07 -0.06 -0.05 -0.05
Altman Z-Score		 18.49 12.94 15.16 11.43 8.06 10.87 18.29 17.68 14.40 0.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.64 18.56 21.65 20.32 16.71 12.26 16.67 14.94 11.47 9.46
Quick Ratio		 17.29 18.21 21.10 19.96 16.44 12.02 16.34 14.69 11.28 9.24
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -27 -28 -21 -25 -24 -27 -32 -33 271
Operating Cash Flow to CapEx		 -5,514.44% -221,083.33% -99,644.44% -26,684.38% -145,135.00% -214,425.00% -58,147.62% -265,812.50% 0.00% 72,347.04%
Free Cash Flow to Firm to Interest Expense		 0.00 -119.70 -76.66 -53.52 -60.69 -60.74 -67.77 -77.62 -80.66 672.86
Operating Cash Flow to Interest Expense		 0.00 -115.85 -98.55 -66.19 -71.85 -87.08 -122.72 -104.75 -105.44 667.82
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -115.90 -98.65 -66.44 -71.90 -87.12 -122.93 -104.79 -105.44 666.90
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.43
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -8.15 -8.55 -1.52 -8.06 -13 -17 -13 -16 -22 -304
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.34
Increase / (Decrease) in Invested Capital		 1.54 2.80 2.31 -7.29 -5.21 -8.80 -11 -7.97 -8.69 -287
Enterprise Value (EV)		 486 401 440 256 234 653 1,066 1,086 1,052 -41
Market Capitalization		 914 830 837 724 677 1,068 1,584 1,569 1,497 677
Book Value per Share		 $6.27 $6.28 $5.77 $6.72 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32
Tangible Book Value per Share		 $6.27 $6.28 $5.77 $6.72 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32
Total Capital		 420 429 404 469 439 407 514 475 433 423
Total Debt		 0.00 9.16 9.20 9.24 9.29 9.33 9.38 9.42 9.47 9.52
Total Long-Term Debt		 0.00 9.16 9.20 9.24 9.29 9.33 9.38 8.58 7.76 6.92
Net Debt		 -428 -429 -397 -468 -443 -415 -518 -482 -446 -718
Capital Expenditures (CapEx)		 0.38 0.01 0.04 0.10 0.02 0.02 0.08 0.02 0.00 0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -16 -8.68 -15 -20 -27 -22 -24 -31 -59
Debt-free Net Working Capital (DFNWC)		 412 422 397 462 432 397 506 467 425 669
Net Working Capital (NWC)		 412 422 397 462 432 397 506 466 423 666
Net Nonoperating Expense (NNE)		 9.89 8.50 8.47 9.17 8.87 10 11 11 12 3.50
Net Nonoperating Obligations (NNO)		 -428 -429 -397 -468 -443 -415 -518 -482 -446 -718
Total Depreciation and Amortization (D&A)		 0.56 -0.38 -1.37 -1.78 -2.55 -2.40 -2.91 -3.22 -3.10 -2.54
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -108.89%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,241.07%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,236.23%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Adjusted Diluted Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.90M 68.44M 68.44M 74.24M 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -25 -26 -28 -30 -33 -38 -39 -42 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29.17%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31.92%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -153.52 -100.46 -103.37 -105.13 -118.69 -136.81 -138.93 -145.35 -55.72
NOPAT to Interest Expense		 0.00 -107.46 -70.32 -72.36 -73.59 -83.08 -95.77 -97.25 -101.74 -39.00
EBIT Less CapEx to Interest Expense		 0.00 -153.57 -100.55 -103.62 -105.18 -118.73 -137.03 -138.97 -145.35 -56.64
NOPAT Less CapEx to Interest Expense		 0.00 -107.52 -70.42 -72.60 -73.64 -83.12 -95.98 -97.29 -101.74 -39.93
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Kura Oncology has demonstrated some consistent financial trends across recent quarters and years, primarily characterized by ongoing losses but improved cash flow and liquidity.

  • Total revenue was reported at $53.9 million in Q4 2024, marking revenue generation progress as prior quarters in 2024 and recent years showed zero revenue.
  • Net cash from operating activities turned positive to $269 million in Q4 2024, up significantly from negative cash flows in previous quarters, reflecting better operational cash management or working capital changes.
  • The company's cash and short-term investments remain substantial, with cash and equivalents increasing from about $27 million in Q1 2023 to over $49 million by Q3 2024 and investments fluctuating but staying over $400 million, indicating strong liquidity to fund operations.
  • Continuous net losses persisted each quarter, with Q4 2024 net loss at $19.2 million, albeit lower in magnitude than earlier quarters in the year, indicating ongoing investment in development but still a lack of profitability.
  • Selling, General & Administrative (SG&A) and Research & Development (R&D) expenses have steadily increased over the periods, with R&D reaching $52.3 million in Q4 2024, showing sustained heavy investment in pipeline and product development.
  • Operating expenses have risen, with total operating expenses hitting $76.3 million in Q4 2024, reflecting increased operational scale but contributing to ongoing operating losses.
  • Despite revenue growth in Q4 2024, net losses continue to impact retained earnings, which remain deeply negative around -$876 million as of Q3 2024, indicating accumulated deficits.
  • Basic and diluted EPS remain negative across all recent quarters, with -$0.21 per share in Q4 2024 versus around -$0.5 to -$0.6 per share in 2023, showing no profitability for shareholders yet.
  • Interest expense has slightly increased from $229K in Q4 2022 to around $403K in Q4 2024, adding some financial costs, though still modest given overall scale.
  • Total liabilities have increased from about $35 million in mid-2023 to $55 million by Q3 2024, driven by slight increases in short-term and long-term debt, which could pressure future cash flows.

Summary: Kura Oncology is progressing towards revenue generation with improving cash flow from operations, supported by strong liquidity from cash and investments. However, the company continues to invest heavily in R&D leading to consistent quarterly losses and negative equity. Shareholders are yet to see profitability, and the company’s ongoing operational losses and expenses highlight the typical biotech risk profile. Investors should weigh the potential of revenue growth and pipeline success against sustained losses and high cash burn.

08/09/25 03:05 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Kura Oncology's Financials

When does Kura Oncology's financial year end?

According to the most recent income statement we have on file, Kura Oncology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Kura Oncology's net income changed over the last 2 years?

Kura Oncology's net income appears to be on an upward trend, with a most recent value of -$173.98 million in 2024, rising from -$135.84 million in 2022. The previous period was -$152.63 million in 2023. See where experts think Kura Oncology is headed by visiting Kura Oncology's forecast page.

What is Kura Oncology's operating income?
Kura Oncology's total operating income in 2024 was -$193.20 million, based on the following breakdown:
  • Total Gross Profit: $53.88 million
  • Total Operating Expenses: $247.08 million
How has Kura Oncology's revenue changed over the last 2 years?

Over the last 2 years, Kura Oncology's total revenue changed from $0.00 in 2022 to $53.88 million in 2024, a change of 5,388,300,000.0%.

How much debt does Kura Oncology have?

Kura Oncology's total liabilities were at $346.52 million at the end of 2024, a 570.7% increase from 2023, and a 861.8% increase since 2022.

How much cash does Kura Oncology have?

In the past 2 years, Kura Oncology's cash and equivalents has ranged from $37.32 million in 2023 to $224.46 million in 2024, and is currently $224.46 million as of their latest financial filing in 2024.

How has Kura Oncology's book value per share changed over the last 2 years?

Over the last 2 years, Kura Oncology's book value per share changed from 6.28 in 2022 to 5.32 in 2024, a change of -15.3%.


Related Companies

This page (NASDAQ:KURA) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners
Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
Crypto 101 Media | Sponsored
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsored
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsored
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...
The Oxford Club | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
Crypto Income (almost instantly)
How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...
Awesomely, LLC | Sponsored
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump c...
Weiss Ratings | Sponsored